KR101157334B1 - Ｆｘｒ을 조절하기 위한 화합물 및 방법 - Google Patents

Ｆｘｒ을 조절하기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR101157334B1
KR101157334B1 KR1020107000896A KR20107000896A KR101157334B1 KR 101157334 B1 KR101157334 B1 KR 101157334B1 KR 1020107000896 A KR1020107000896 A KR 1020107000896A KR 20107000896 A KR20107000896 A KR 20107000896A KR 101157334 B1 KR101157334 B1 KR 101157334B1
Authority
KR
South Korea
Prior art keywords
phenyl
cyclopropyl
dichloro
isoxazol
ylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107000896A
Other languages
English (en)
Korean (ko)
Other versions
KR20100020999A (ko
Inventor
마이클 제임스 제닌
프란시스코 하비에르 아헤하스-치차로
아나 벨렌 부에노 멜렌도
피터 루돌프 매니넌
앨런 엠. 워쇼스키
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20100020999A publication Critical patent/KR20100020999A/ko
Application granted granted Critical
Publication of KR101157334B1 publication Critical patent/KR101157334B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
KR1020107000896A 2007-07-16 2008-07-11 Ｆｘｒ을 조절하기 위한 화합물 및 방법 Expired - Fee Related KR101157334B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16
US60/949,974 2007-07-16
PCT/US2008/069719 WO2009012125A1 (en) 2007-07-16 2008-07-11 Compounds and methods for modulating fxr

Publications (2)

Publication Number Publication Date
KR20100020999A KR20100020999A (ko) 2010-02-23
KR101157334B1 true KR101157334B1 (ko) 2012-06-15

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107000896A Expired - Fee Related KR101157334B1 (ko) 2007-07-16 2008-07-11 Ｆｘｒ을 조절하기 위한 화합물 및 방법

Country Status (31)

Country Link
US (1) US8153624B2 (enExample)
EP (1) EP2178851B1 (enExample)
JP (1) JP5373788B2 (enExample)
KR (1) KR101157334B1 (enExample)
CN (1) CN101743232B (enExample)
AR (1) AR067540A1 (enExample)
AT (1) ATE539065T1 (enExample)
AU (1) AU2008276236B2 (enExample)
BR (1) BRPI0814571A2 (enExample)
CA (1) CA2693406C (enExample)
CL (1) CL2008002051A1 (enExample)
CO (1) CO6270212A2 (enExample)
CY (1) CY1112298T1 (enExample)
DK (1) DK2178851T3 (enExample)
DO (1) DOP2010000018A (enExample)
EA (1) EA016475B1 (enExample)
EC (1) ECSP109879A (enExample)
ES (1) ES2376176T3 (enExample)
HR (1) HRP20120048T1 (enExample)
IL (1) IL202234A0 (enExample)
MA (1) MA31683B1 (enExample)
MX (1) MX2010000502A (enExample)
PE (1) PE20090809A1 (enExample)
PL (1) PL2178851T3 (enExample)
PT (1) PT2178851E (enExample)
RS (1) RS52216B (enExample)
SI (1) SI2178851T1 (enExample)
SV (1) SV2010003458A (enExample)
TN (1) TN2010000028A1 (enExample)
TW (1) TW200906823A (enExample)
WO (1) WO2009012125A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (en) * 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012087520A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655369A1 (en) * 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
ES2846183T3 (es) 2013-09-11 2021-07-28 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la infección por el virus de la hepatitis B
BR112016009630B1 (pt) * 2013-11-05 2021-02-09 Novartis Ag receptores de farnesoide x, seus usos, combinação e composição farmacêutica
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
AU2016215179B2 (en) 2015-02-06 2021-02-25 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PE20180034A1 (es) 2015-04-07 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
SG11201808607SA (en) 2016-03-28 2018-11-29 Intercept Pharmaceuticals Inc Medicine obtained by combining fxr agonist and arb
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189651A1 (en) * 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA3026512A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
MA55632A (fr) * 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
KR20210110407A (ko) * 2016-09-14 2021-09-07 노파르티스 아게 Fxr 작용제의 신규 요법
JP2019537557A (ja) * 2016-10-04 2019-12-26 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
NZ758117A (en) 2017-04-12 2022-01-28 Il Dong Pharma Isoxazole derivatives as nuclear receptor agonists and uses thereof
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
WO2019055808A1 (en) 2017-09-14 2019-03-21 Ardelyx, Inc. HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS
KR102731924B1 (ko) 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
KR102732404B1 (ko) * 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 알켄 화합물
JP7264905B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしての多環化合物
SG11202003827YA (en) * 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
AU2018360575A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US11667629B2 (en) 2017-12-22 2023-06-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Isoxazole derivative, preparation method therefor, and use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
AU2018438845A1 (en) * 2018-08-30 2021-04-01 Terns Pharmaceuticals, Inc. Treating liver disorders
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
LT3911647T (lt) 2019-01-15 2024-03-25 Gilead Sciences, Inc. Izoksazolo junginys kaip fxr agonistas ir jį apimančios farmacinės kompozicijos
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US12319676B2 (en) 2019-02-15 2025-06-03 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid X receptor modulators
EP3924329A2 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
JP7465883B2 (ja) 2019-02-15 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
SG11202111502XA (en) 2019-04-19 2021-11-29 Shanghai Institute Of Materia Medica Chinese Academy Of Sciences Fxr small molecule agonist and preparation method therefor and use thereof
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CA3142358A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
IL292459A (en) * 2019-11-08 2022-06-01 Terns Pharmaceuticals Inc Treatment of liver disorders
WO2021108974A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
EP4090327B1 (en) 2020-01-15 2025-03-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
EP4149452A4 (en) * 2020-05-13 2024-05-01 Terns Pharmaceuticals, Inc. COMBINATION TREATMENT OF LIVER DISEASES
IL300853A (en) 2020-08-25 2023-04-01 Lilly Co Eli Polymorphs of an ssao inhibitor
IL301238A (en) * 2020-09-11 2023-05-01 Terns Pharmaceuticals Inc Solid dispersion formulations of an fxr agonist
EP4229043A4 (en) * 2020-10-15 2025-01-08 Eli Lilly and Company POLYMORPHS OF AN FXR AGONIST
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
AU2022387121A1 (en) 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis
CN115850152B (zh) * 2022-12-20 2025-10-31 河北鼎泰制药有限公司 一种杂质A-7-imp3的制备方法及其用途
EP4568664A1 (en) 2023-04-07 2025-06-18 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
JP4541883B2 (ja) 2002-07-09 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満症薬として有用な置換へテロ環誘導体、並びに方法
EP1984360B1 (en) 2006-02-03 2014-01-15 Eli Lilly & Company Compounds and methods for modulating FX-receptors
PL2029547T3 (pl) * 2006-05-24 2010-09-30 Lilly Co Eli Agoniści FXR
ATE460403T1 (de) * 2006-05-24 2010-03-15 Lilly Co Eli Verbindungen und verfahren zur modulierung von fx-rezeptoren

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists

Also Published As

Publication number Publication date
AR067540A1 (es) 2009-10-14
US8153624B2 (en) 2012-04-10
MA31683B1 (fr) 2010-09-01
IL202234A0 (en) 2010-06-16
PL2178851T3 (pl) 2012-05-31
JP5373788B2 (ja) 2013-12-18
AU2008276236B2 (en) 2013-03-14
SV2010003458A (es) 2011-01-10
EP2178851B1 (en) 2011-12-28
PE20090809A1 (es) 2009-06-27
AU2008276236A1 (en) 2009-01-22
EA016475B1 (ru) 2012-05-30
US20100152166A1 (en) 2010-06-17
ES2376176T3 (es) 2012-03-09
MX2010000502A (es) 2010-03-26
KR20100020999A (ko) 2010-02-23
CY1112298T1 (el) 2015-12-09
EP2178851A1 (en) 2010-04-28
TW200906823A (en) 2009-02-16
CN101743232A (zh) 2010-06-16
HRP20120048T1 (hr) 2012-02-29
RS52216B (sr) 2012-10-31
BRPI0814571A2 (pt) 2015-01-06
PT2178851E (pt) 2012-02-27
CN101743232B (zh) 2013-03-06
JP2010533722A (ja) 2010-10-28
SI2178851T1 (sl) 2012-02-29
EA201070148A1 (ru) 2010-06-30
CO6270212A2 (es) 2011-04-20
DK2178851T3 (da) 2012-02-06
TN2010000028A1 (en) 2011-09-26
ATE539065T1 (de) 2012-01-15
ECSP109879A (es) 2010-02-26
CL2008002051A1 (es) 2009-05-29
CA2693406A1 (en) 2009-01-22
DOP2010000018A (es) 2010-01-31
WO2009012125A1 (en) 2009-01-22
CA2693406C (en) 2014-04-29

Similar Documents

Publication Publication Date Title
KR101157334B1 (ko) Ｆｘｒ을 조절하기 위한 화합물 및 방법
ES2340221T3 (es) Compuestos y procedimientos para modular fxr.
KR101712466B1 (ko) 신규의 에프엑스알(엔알 1에이치4) 결합 및 활성 조절 화합물
ES2255294T3 (es) Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
EA015632B1 (ru) Агонисты fxr
WO2005087710A1 (ja) アミノフェニルプロパン酸誘導体
TW201141866A (en) Novel spiropiperidine compounds
WO2015024448A1 (zh) 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
TW200536832A (en) Process for producing 5-hydroxy-4-thiomethylpyrazole compound
WO2012174685A1 (zh) 一种2-取代-2h-1，2，3-三氮唑衍生物的制备方法
Li et al. Design, synthesis, and biological evaluation of phenyloxadiazole derivatives as potential antifungal agents against phytopathogenic fungi
TW200800150A (en) Compounds with medicinal effects due to interaction with the glucocorticoid receptor
JP2023545677A (ja) Ｆｘｒ小分子アゴニストとその調製方法および用途
JP2008539181A (ja) Ｅｐ１受容体アンタゴニストとして有用なフラン化合物
CN114195776A (zh) 新型fxr小分子激动剂制备及其用途
JP3977222B2 (ja) シクロオキシゲナーゼ−２阻害剤として選択性の優れた３，４−ジヒドロ−１ｈ−ナフタレン誘導体
JP7450951B2 (ja) 新型ｆｘｒ小分子作動剤の製造およびその使用
ES2342222T3 (es) Agonistas de fxr.
JPH09151180A (ja) ３−（フェニルアルキルアミノアルキルオキシ）−ヘテロアリール−化合物、この化合物を含有する抗虚血性医薬並びにこの化合物を製造するための方法及び中間生成物

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170612

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170612